Compare OTLK & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTLK | SY |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 272.8M |
| IPO Year | 2016 | 2018 |
| Metric | OTLK | SY |
|---|---|---|
| Price | $1.41 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.50 | ★ $5.50 |
| AVG Volume (30 Days) | ★ 11.8M | 441.8K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | $38.64 |
| Revenue Next Year | $173.23 | $30.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $1.28 |
| 52 Week High | $3.39 | $6.28 |
| Indicator | OTLK | SY |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 47.26 |
| Support Level | $1.21 | $1.28 |
| Resistance Level | $1.54 | $1.79 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 17.54 | 62.22 |
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.